… the patients who contracted the ILD. We report a case of severe ILD in a … patient treated
with gefitinib. She experienced partial response with restarted low-dose EGFR-TKI erlotinib and …

… Erlotinib had minimal activity in unselected previously treated women with … Two patients
had a partial response, and eight patients had stable disease as their best response to erlotinib …

… This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for
… first cross-over response to erlotinib after gefitinib failure in a patient with an activating EGFR …

… In total, 3 out of the 20 evaluable patients with hepatocellular cancer had a partial response
(… In a Phase II trial in untreated patients with gastric and GEJ adenocarcinoma, erlotinib did …

… We obtained two partial responses and three stable diseases with erlotinib with a median
duration of response of 8 months. The median time to progression and overall survival were …

… response rate. Results: Of the 46 patients, 13 were assessed to have a partial response
and … The median duration of response was 449 days and time to progression was 75 days. …

… patients, one had a partial response and one stable disease, resulting in an objective response
… These two patients benefited from erlotinib for 6.2 months and 7.8 months, respectively; …

… A complete or partial response to erlotinib was seen in 5 of 17 patients (29.4%) with
grade 2 rash, 2 of 26 patients (7.7%) with grade 1 rash, and 0 of 15 patients with no rash.[26] …

… with EGFR WT, clinical benefit rate (CBR), defined as stable disease and partial response,
was 41% (16 of 39) in the erlotinib plus fulvestrant arm and 8.3% (1 of 12) in the …

… Two patients with PR to erlotinib treatment were female never smokers with … both had
partial response to prior gefitinib treatment. Three of four patients with a SD to erlotinib treatment …